PROCEPT BioRobotics Corporation
PRCT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PRCT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PRCT
PROCEPT BioRobotics Corporation is a commercial-stage medical device company focused on developing and marketing Aquablation therapy for the surgical treatment of benign prostatic hyperplasia (BPH).
Key risk: History of losses
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials for PROCEPT BioRobotics Corporation.
PROCEPT BioRobotics Corporation is a commercial-stage medical device company focused on developing and marketing Aquablation therapy for the surgical treatment of benign prostatic hyperplasia (BPH).
- PROCEPT BioRobotics develops and markets Aquablation therapy, a minimally invasive surgical treatment for benign prostatic hyperplasia (BPH) [sec_mda].
- As of June 30, 2026, the company reported cash and cash equivalents of $227.9 million, an accumulated deficit of $700.1 million, and $52.0 million outstanding on its loan facility [sec_mda · as of 2026-08-05].
- For the six months ended June 30, 2026, the company generated total revenue of $94.5 million and reported a net loss of $26.9 million [latest reported financials].
- The company expects expenses to increase as it continues to invest in sales and marketing, operations, and research and development [sec_mda · as of 2026-08-05].
- PROCEPT BioRobotics believes its existing cash and anticipated revenue will be sufficient to fund operations for at least the next twelve months from the issuance date of its financial statements [sec_mda · as of 2026-04-30].
What works
- The company has a commercially approved therapy (Aquablation) for a large patient population (BPH) and is generating growing revenue, with $94.5M in the first half of 2026 [latest reported financials].
- PROCEPT holds a strong cash position of $227.9M as of June 30, 2026, which management believes is sufficient to fund operations for at least the next twelve months [sec_mda · as of 2026-08-05].
- The company is making substantial investments in sales, marketing, and R&D, indicating a strategy to expand market adoption and develop its pipeline [sec_mda · as of 2026-08-05].
What to weigh
- The company has a significant accumulated deficit of $700.1 million as of June 30, 2026, reflecting a history of losses [sec_mda · as of 2026-08-05].
- PROCEPT continues to report net losses ($26.9M net loss in the first half of 2026) and expects expenses to increase, which may pressure future profitability [latest reported financials] [sec_mda · as of 2026-08-05].
- The company's future funding requirements depend on uncertain factors such as market acceptance of Aquablation therapy and the emergence of competing technologies [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
Cash and cash equivalents as of June 30, 2026
“As of June 30, 2026, we had cash and cash equivalents of $227.9 million”
SEC MD&A · August 5, 2026
Accumulated deficit as of June 30, 2026
“an accumulated deficit of $700.1 million”
SEC MD&A · August 5, 2026
Expectation of increasing expenses
“We expect our expenses will increase for the foreseeable future, as we continue to make substantial investments in sales and marketing, operations and research and development.”
SEC MD&A · August 5, 2026
Risks & what to watch (4)›
Key risks
- History of losses — Accumulated deficit of $700.1M as of June 30, 2026, with ongoing net losses [sec_mda · as of 2026-08-05].
- Dependence on market acceptance — Future revenue depends on the degree and rate of market acceptance of Aquablation therapy [sec_mda · as of 2026-08-05].
- Competitive and technological risks — Emergence of competing technologies or other adverse market developments could impact the business [sec_mda · as of 2026-04-30].
- Need for additional capital — If existing cash and revenue are insufficient, the company may need to seek additional financing [sec_mda · as of 2026-04-30].
What to watch
- Quarterly revenue growth and progress toward profitability, as the company continues to invest in commercialization [sec_mda · as of 2026-08-05].
- Updates on clinical trials and regulatory clearances for Aquablation therapy, which could expand the addressable market [sec_mda · as of 2026-08-05].
- Cash burn rate and any changes to the company's liquidity position or debt facility [sec_mda · as of 2026-08-05].
- Competitive developments in the BPH treatment landscape, including new technologies or therapies [sec_mda · as of 2026-04-30].
Sources: Catalysts · SEC MD&A · Generated August 16, 2026 · How we verify sources →
Run PROCEPT BioRobotics Corporation through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PROCEPT BioRobotics Corporation facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
44.8 months
D/E 0.41 · 0% dilution
Lead: Approved
1 candidate
No upcoming catalysts tracked
8 buys · 11 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
255
Total value held
$1.33B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,798,134 | $120.0M |
| blackrock, inc. | 4,362,002 | $109.1M |
| bnp paribas asset management holding s.a. | 3,089,378 | $77.3M |
| vanguard portfolio management llc | 2,421,362 | $60.6M |
| prosight management, lp | 1,945,000 | $48.6M |
| mackenzie financial corp | 1,720,738 | $43.0M |
| state street corp | 1,529,631 | $38.3M |
| fmr llc | 1,461,904 | $36.6M |
| geode capital management, llc | 1,363,500 | $34.1M |
| artisan partners limited partnership | 1,187,349 | $29.7M |
Showing top 10 of 255 institutional holders of PROCEPT BioRobotics Corporation. Open the full 13F history after sign-in.
Short Interest
as of May 11, 2026- % of float
- 10.6%
- Days to cover
- 4.5
- Shares short
- 5,832,329
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PRCT short interestGovernance
Frequently asked questions
What is the AI investment thesis for PROCEPT BioRobotics Corporation?
PROCEPT BioRobotics Corporation is a commercial-stage medical device company focused on developing and marketing Aquablation therapy for the surgical treatment of benign prostatic hyperplasia (BPH).
What is PROCEPT BioRobotics Corporation's lead drug candidate?
PROCEPT BioRobotics Corporation's most advanced tracked candidate is aquablation therapy (Approved) for Benign prostatic hyperplasia (BPH).
Who is the CEO of PROCEPT BioRobotics Corporation?
Mr. Larry L. Wood is the chief executive officer of PROCEPT BioRobotics Corporation (PRCT).
Where is PROCEPT BioRobotics Corporation headquartered?
PROCEPT BioRobotics Corporation (PRCT) is headquartered in San Jose, CA, United States.
What therapeutic areas does PROCEPT BioRobotics Corporation focus on?
PROCEPT BioRobotics Corporation develops therapies across Oncology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.